Ivermectin Dosing for Scabies in Children
For children weighing ≥15 kg, administer oral ivermectin 200 µg/kg on day 0 and repeat the identical dose on day 14, both doses taken with food; for children <15 kg, ivermectin is contraindicated and permethrin 5% cream applied to the entire body (including scalp, face, and neck) for 8–14 hours is the required first-line therapy. 1, 2
Weight and Age Criteria for Ivermectin Use
Children must weigh ≥15 kg to receive ivermectin because the immature blood-brain barrier in smaller children permits potential neurotoxic CNS penetration, even though serious adverse events have not been documented in limited off-label series. 1, 2
The 15 kg threshold typically corresponds to children ≥5 years of age, though weight is the definitive criterion rather than age alone. 1
Ivermectin is absolutely contraindicated in children <15 kg due to theoretical risk of CNS toxicity from drug crossing an incompletely developed blood-brain barrier. 1, 2
Standard Ivermectin Dosing Protocol (≥15 kg)
Administer 200 µg/kg orally on day 0 and repeat the same dose on day 14. 1, 2, 3
Both doses must be taken with food—preferably a substantial or high-fat meal—because food increases systemic exposure approximately 2.5-fold, while fasting reduces absorption by ~60%. 1, 2
The day-14 repeat dose is mandatory because ivermectin has limited ovicidal activity and cannot eradicate eggs present at the initial treatment; omitting this second dose is the leading cause of treatment failure. 1, 2
Alternative Therapy for Children <15 kg
Permethrin 5% cream is the required first-line treatment for all children weighing <15 kg. 1, 2
Apply permethrin to the entire body—including scalp, face, neck, temples, and forehead—and leave on for 8–14 hours before rinsing. 2
Permethrin is safe for infants as young as 2 months and is explicitly recommended for pregnant and lactating women, making it appropriate for all vulnerable populations. 2
A second application should be given 7–10 days after the first dose to address any newly hatched larvae. 2
Emerging Evidence on Younger Children
Recent pharmacokinetic modeling suggests lower-weight dosing may be feasible:
A 3 mg dose in children aged 2–4 years weighing 10–14 kg achieved comparable drug exposure to the standard 200 µg/kg dose in older children and resulted in 90% complete resolution by day 14 with only mild adverse effects in 7%. 4
For infants 3–7 months, a 0.75 mg dose (one-quarter tablet); for 8–12 months, 1.5 mg (one-half tablet); and for 13–24 months, 3 mg (one tablet) achieved target exposures in simulation studies. 5
Off-label ivermectin use in 170 children <15 kg (mean dose 223 µg/kg) resulted in only 7 mild adverse events (4%) with 85% healing, though this remains off-label and should be reserved for specialist consultation after permethrin failure. 6
Critical Management Points
Treat all household contacts simultaneously with the same regimen (even if asymptomatic) to prevent apparent treatment failure from reinfection. 1, 2
Machine-wash and hot-dry all bedding and clothing, or isolate items from body contact for ≥72 hours. 1, 2
Post-treatment pruritus may persist up to 2 weeks and does not indicate failure; retreatment is warranted only if live mites are demonstrated after 14 days. 1, 2
Never use lindane in children <10 years due to seizure risk and association with neural-tube defects. 2
Comparative Efficacy: Ivermectin vs. Permethrin
A 2026 cluster-randomized trial of 1,075 participants showed permethrin 5% cream was statistically superior to ivermectin (88.5% vs 71.8% cluster cure rate; −16.7 percentage point difference, 95% CI −26.3 to −7.1), though both were given on days 0 and 10. 7
Despite this trial, current CDC and AAP guidelines continue to endorse ivermectin 200 µg/kg (days 0 and 14) as an equally effective alternative to permethrin based on its established safety profile, ease of administration, and comparable efficacy in prior studies. 1, 2
Common Pitfalls
Applying permethrin immediately after a hot bath increases systemic absorption through vasodilation; allow skin to cool first. 2
Treating the child in isolation without simultaneous household treatment is the most common cause of apparent failure. 2
Premature retreatment for residual itching within 2 weeks leads to unnecessary medication exposure and cost without clinical benefit. 1, 2